Development Milestone Fee. Within ten (10) business days after receipt by Licensee, its Affiliates or Designee of the first marketing approval for a Licensed Product from the United States Food and Drug Administration or any successor agency or authority thereto ("FDA"), Licensee shall pay to Genentech a non-creditable, non-refundable development milestone fee of [ *** ].
Appears in 1 contract
Sources: Non Exclusive Patent License Agreement (Inhibitex Inc)
Development Milestone Fee. Within ten (10) business days after receipt by Licensee, its Affiliates or Designee of the first marketing approval for a Licensed Product from the United States Food and Drug Administration or any successor agency or authority thereto ("FDA"), Licensee shall pay to Genentech a non-creditable, non-refundable development milestone fee of [ [*** *].
Appears in 1 contract
Sources: Non Exclusive Patent License Agreement (Peregrine Pharmaceuticals Inc)